Browsing by Author "Wanume, Benon"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Severe malaria readmissions in Northern Uganda: a cross‑sectional study
    (Malaria Journal, 2025-02-27) Olum, James; Mukunya, David; Nambozo, Brendah; Wanume, Benon; Kakuru, Abel
    Malaria is a critical global health issue, particularly for children in endemic regions. However, factors associated with recurrent severe malaria in children under 5 years of age in Northern Uganda are poorly understood. This study aimed to identify factors associated with readmission due to severe malaria within six months post-discharge among children in this age group.
  • Thumbnail Image
    Item
    Side-Effects following Oxford/AstraZeneca COVID-19 Vaccine in Tororo District, Eastern Uganda: A Cross-Sectional Study
    (MDPI AG, 2022-11) Onyango, Jagire; Mukunya, David; Napyo, Agnes; Nantale, Ritah; Makoko, Brian T; Matovu, Joseph K B; Wanume, Benon; Okia, David; Okello, Francis; Okware, Sam; Olupot-Olupot, Peter; Lubaale, Yovani
    Abstract: Effective, safe and proven vaccines would be the most effective strategy against the COVID-19 pandemic but have faced rollout challenges partly due to fear of potential side-effects. We assessed the prevalence, profiles, and predictors of Oxford/AstraZeneca vaccine side-effects in Tororo district of Eastern Uganda. We conducted telephone interviews with 2204 participants between October 2021 and January 2022. Multivariable logistic regression was conducted to assess factors associated with Oxford/AstraZeneca vaccine side-effects using Stata version 15.0. A total of 603/2204 (27.4%) of the participants experienced one or more side-effects (local, systemic, allergic, and other side-effects). Of these, 253/603 (42.0%) experienced local side-effects, 449/603 (74.5%) experienced systemic side-effects, 11/603 (1.8%) experienced allergic reactions, and 166/603 (27.5%) experienced other side-effects. Ten participants declined to receive the second dose because of side-effects they had experienced after the first dose. Previous infection with COVID-19 (adjusted odds ratio (AOR): 4.3, 95% confidence interval (95% CI): 2.7–7.0), being female (AOR: 1.3, 95% CI: 1.1–1.6) and being a security officer (AOR: 0.4, 95% CI: 0.2–0.6) were associated with side-effects to the Oxford/AstraZeneca vaccine. We recommend campaigns to disseminate correct information about potential side-effects of the Oxford/AstraZeneca vaccine and strengthen surveillance for adverse events following vaccination.